Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$6.99−$0.5000 (−6.68%) on the dayAs of the close; data may be delayed.
ARTV price, last 12 months
Key stats
- Previous close
- $7.49
- Open
- $7.48
- Day range
- $6.90 – $7.49
- 52-week range
- $2.71 – $14.53
- Volume
- 507.1K
- Avg volume (20 days)
- 465.1K
- Market cap
- $341.7M
Performance
1W−18.8%
1M−40.6%
3M−27.3%
6M+35.5%
YTD+62.9%
1Y+142.7%
vs S&P 500, 1Y+125.9 pts
Technicals and fundamentals
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $341.7M